Meningococcal Conjugate Vaccine Effective in Chad

A serogroup A meningococcal vaccine was highly effective in preventing invasive disease and carriage.

Regions of Africa have large, seasonal epidemics of meningococcal meningitis, usually serogroup A. In Chad, epidemics have persisted despite the use of polysaccharide vaccine given in response to outbreaks. Conjugate vaccines offer potential advantages — immunogenicity in young children, induction of immunologic memory, and prevention of pharyngeal carriage. An affordable, monovalent serogroup A polysaccharide–tetanus toxoid conjugate vaccine (PsA-TT) was developed through the Meningitis Vaccine Project, a public–private partnership. Based on safety and immunogenicity data, the vaccine was licensed in India in 2009, and prequalified by the WHO 2010, without a phase III efficacy trial.

Now, investigators have measured the effect of PsA-TT in …

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Meningococcal Conjugate Vaccine Effective in Chad

Topics

Reviewing Author